NanoCarrier Co., Ltd. (3NQ) Price & Analysis

0 Followers

3NQ Stock Chart & Stats

€0.72

€0.00(0.00%)

At close: Jan 08 4:00 PM EST

€0.72

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€0.42 - €1.15

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€40.47M

Enterprise Value€5.36B

Total Cash (Recent Filing)€4.22B

Total Debt (Recent Filing)€1.20B

Price to Earnings (P/E)―

Beta0.68

Next Earnings

Nov 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-13.45

Shares Outstanding90,945,460

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-1.32

Price to Book (P/B)3.10

Price to Sales (P/S)63.30

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue ReboundThe sharp 2026 revenue rebound indicates renewed commercial activity after several years of declines. If sustained, stronger sales can broaden the company’s partnering and licensing base, improve operating leverage, and provide a larger platform for advancing its nanomedicine pipeline.

High Gross MarginsVery high gross margins suggest the company’s sales can carry substantial value after direct costs, consistent with an intellectual-property-led biotechnology model. This economics profile could support future reinvestment and profitability if development assets achieve broader commercialization.

Moderate LeverageModerate leverage and positive equity provide some balance-sheet cushion while the company develops its pipeline and pursues partnerships. Compared with a highly leveraged structure, this may preserve more flexibility for funding research, although operating losses still constrain that benefit.

Bears Say

Persistent Deep LossesPersistent and exceptionally deep losses show that the business remains far from break-even despite the 2026 revenue recovery. Continued losses can erode equity, require repeated financing, and make future operating performance dependent on successful development or partnering outcomes.

Ongoing Cash BurnNegative operating and free cash flow indicates that the core business does not currently fund its own activities. The resulting cash burn increases reliance on external financing or partner payments, limiting resilience and potentially constraining the pace of sustained pipeline investment.

Financial Flexibility ErosionHigher debt alongside declining assets and equity points to weakening financial flexibility over time, even though leverage remains moderate overall. This combination can reduce the company’s capacity to absorb continued development losses and increase dependence on future financing or milestones.

NanoCarrier Co., Ltd. News

Nano Holdings Begins First-in-Human mRNA Trial Targeting Knee Osteoarthritis

NanoCarrier Co., Ltd. ( ($JP:4571) ) has provided an announcement. Nano Holdings, Inc., a Japan-based healthcare value creation...

8M ago

NANO MRNA Advances RUNX1 mRNA Clinical Trial for Osteoarthritis

The latest announcement is out from NanoCarrier Co., Ltd. ( ($JP:4571) ). NANO MRNA Co., Ltd., through its...

1y ago

3NQ FAQ

What was NanoCarrier Co., Ltd.’s price range in the past 12 months?

NanoCarrier Co., Ltd. lowest stock price was €0.42 and its highest was €1.15 in the past 12 months.

What is NanoCarrier Co., Ltd.’s market cap?

NanoCarrier Co., Ltd.’s market cap is €40.47M.

When is NanoCarrier Co., Ltd.’s upcoming earnings report date?

NanoCarrier Co., Ltd.’s upcoming earnings report date is Nov 13, 2026 which is in 30 days.

How were NanoCarrier Co., Ltd.’s earnings last quarter?

NanoCarrier Co., Ltd. released its earnings results on Aug 07, 2026. The company reported -€0.019 earnings per share for the quarter.

Is NanoCarrier Co., Ltd. overvalued?

According to Wall Street analysts NanoCarrier Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NanoCarrier Co., Ltd. pay dividends?

NanoCarrier Co., Ltd. does not currently pay dividends.

What is NanoCarrier Co., Ltd.’s EPS estimate?

NanoCarrier Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NanoCarrier Co., Ltd. have?

NanoCarrier Co., Ltd. has 90,945,460 shares outstanding.

What happened to NanoCarrier Co., Ltd.’s price movement after its last earnings report?

NanoCarrier Co., Ltd. reported an EPS of -€0.019 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of NanoCarrier Co., Ltd.?

Currently, no hedge funds are holding shares in DE:3NQ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NanoCarrier Co., Ltd.

Nano Holdings, Inc. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. The company’s pipeline products include RUNX1 (mRNA) for the treatment knee osteoarthritis and reduces pain; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma multiforme. In addition, it offers cosmetic raw material. The company was formerly known as NANO MRNA Co.,Ltd. and changed its name to Nano Holdings, Inc. in December 2025. Nano Holdings, Inc. was incorporated in 1996 and is headquartered in Minato, Japan.